RA
CORT icon

Rational Advisors’s Corcept Therapeutics CORT Stock Holding History

Rational Advisors’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-4,300
Closed -$83K – 288
2017
Q3 		$83K Sell
4,300
-1,600
-27% -$23.9K 0.04% 256
2017
Q2 		$70K Buy
+5,900
New +$64.1K 0.04% 246

Other funds holding CORT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Prudential Financial
Prudential Financial Newark, New Jersey $91.8B AUM 38.24% 1-Year Est. Return

Rational Advisors's CORT Position: Q4 2017 in Review

Rational Advisors sold out of Corcept Therapeutics (CORT) in Q4 2017, closing a stake of 4,300 shares — an estimated $83K sold.

Rational Advisors first reported a position in CORT in Q2 2017 and held it in 2 quarters. The position peaked at $83K in Q3 2017. 190 funds tracked by Wall St. Rank hold CORT as of Q4 2017.

  • Rational Advisors reported no remaining Corcept Therapeutics position as of Q4 2017 after selling out during the quarter.
  • Rational Advisors sold 4,300 Corcept Therapeutics shares in Q4 2017, an estimated $83K.
  • Rational Advisors first reported a position in Corcept Therapeutics in Q2 2017 and held it in 2 quarters.
  • Rational Advisors's Corcept Therapeutics position peaked at $83K in Q3 2017.
  • 190 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q4 2017.

Based on Rational Advisors's 13F filing for Q4 2017, filed 8 Feb 2018.